Study Caract.

Arguedas (1991)

Aronovitz (1992)

Gehanno (1994)

Hedrik (2001)

Kafetzis (1994)

Kafetzis (1994)

Stutman (1992)

Country

USA

USA and European countries

France

USA

USA, Dominican epublic, Greece

France, Netherlands

USA

Number of participants

122

334

191

303

463

361

530

Ages

6 months - 17 years

3 years - 11 years

6 months and older

6 months - 7 years

4 months - 13 years

4 months - 11 years

6 months - 13 years

Duration of treatment

10 days

10 days

7 - 9 days

10 days

10 days

10 days

10 days

Dose

C: 30 mg/kg/day A/C: 40 mg/kg/day

C: 30 mg/kg/day A/C: 40 mg/kg/day

C: 40 mg/kg/day A/C: 40 mg/kg/day

C: 30 mg/kg/day A/C: 45/6.4 mg/kg/day +

C 45/mg/day

C: 30 mg/kg/day A/C: 40 mg/kg/day

C: 40 mg/kg/day A/C: 40 mg/kg/day

C: 30 mg/kg/day A/C: 40 mg/kg/day

Clinical response

C: 58/60 (96.7%)

A/C: 53/62 (91.3%)

C: 141/168 (84%)

A/C: 129/166 (78%)

C: 83/99 (84%)

A/C: 80/92 (87%)

6 months - 2 years C: 59/70 (80%)

A/C: 64/76 (86%)

2 years - 7 years C: 68/80 (93%)

A/C: 66/77 (92%)

C: 186/223 (83%)

A/C: 193/243 (79%)

C: 145/174 (83%)

A/C: 147/176 (84%)

C: 141/168 (84%)

A/C: 129/166 (78%)

Bacterial response

C: 57/60 (95%)

A/C: 57/62 (91.3%)

C: 142/168 (85%)

A/C: 136/166 (81%)

C: 115/130 (88%)

A/C: 118/132 (89%)

No presented data

C: 158/188 (84%)

A/C: 171/214 (80%)

C: 109/131 (83%)

A/C: 111/214 (80%)

C: 165/193 (85%)

A/C: 149/182 (82%)

Frequency of adverse effects

C: 20/60 (33%)

A/C: 43/62 (69%)

<3 years C: 35/160 (22%)

A/C: 56/163 (34%)

>3 years C: 8/103 (8%)

A/C: 18/104 (17%)

<3 years C: 21/114 (18%)

A/C: 36/131 (27%)

>3 years C: 14/69 (20%)

A/C: 14/47 (30%)

C: 28/150 (19%)

A/C: 49/153 (32%)

C: 32/223 (14%)

A/C: 86/243 (35%)

C: 24/183 (13%)

A/C: 36/178 (20%)

<3 years C: 37/160 (23%)

A/C: 72/163 (44%)

>3 years C: 5/103 (5%)

A/C: 17/104 (16%)